Viral envelope disruption

Viral envelope disruption is a strategy for antiviral therapy that involves damaging or destabilizing the lipid envelope surrounding many pathogenic viruses, leading to loss of infectivity. This can be achieved by small molecules (e.g., molecular tweezers like CLR01, photosensitizers like LJ001), which bind or intercalate into the envelope lipids, altering membrane structure, promoting oxidative damage, or increasing surface tension, thus rendering the virus non-infectious. Such agents are generally broad-spectrum against enveloped viruses (e.g., HIV, Ebola, SARS-CoV-2, influenza) but have minimal effect against non-enveloped viruses. This is not a protein or receptor, but a physical-chemical process that disables the virus by destroying a structure essential for host cell entry. Selectivity for viral envelopes is crucial to minimize toxicity toward host cells.

Other names

Envelope lysisviral membrane disruptiondisruption of viral envelopeviral membrane lysis

Intercalation into the viral lipid envelope, disturbing membrane structure or generating reactive oxygen species (e.g. singlet oxygen) to oxidize and disrupt the membrane. Direct binding to membrane lipids, altering their orientation and/or biophysical properties to increase surface tension and cause envelope rupture. Prevention of viral fusion by changing the required membrane curvature or structural organization for entry.